bluebird bio (BLUE) PT Raised to $9 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts BLUE Hot Sheet
Price: $4.97 --0%
Rating Summary:
10 Buy, 19 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 22 | Down: 25 | New: 18
Rating Summary:
10 Buy, 19 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 22 | Down: 25 | New: 18
Join SI Premium – FREE
BofA Securities analyst Jason Gerberry raised the price target on bluebird bio (NASDAQ: BLUE) to $9.00 (from $8.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Goldman Sachs upgrades Sirius XM Radio to Buy with $37 target
- Bright Minds Biosciences Inc. (DRUG) PT Lowered to $37 at BTIG
- Estee Lauder (EL) PT Raised to $129 at Goldman Sachs
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
